We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Immuneering Corporation | NASDAQ:IMRX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.06 | -3.90% | 1.48 | 1.48 | 1.56 | 1.57 | 1.46 | 1.57 | 184,023 | 23:08:46 |
Format: Company Presentation and 1x1 Investor MeetingsPresentation: June 8 from 10:00 – 10:25 am ET in Track 2
The presentations will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.
About Immuneering Corporation
Immuneering is a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. The company’s development pipeline also includes IMM-6-415, a universal-MAPK program, as well as several early-stage programs. For more information, please visit www.immuneering.com.
Media Contact:Gina Nugent Nugent Communications 617-460-3579 gina@nugentcommunications.com
Investor Contacts: Laurence Watts Gilmartin Group 619-916-7620 laurence@gilmartinir.com
or
Kiki Patel, PharmD Gilmartin Group 332-895-3225kiki@gilmartinir.com
1 Year Immuneering Chart |
1 Month Immuneering Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions